March 19, 2024
The Globe and Mail | AstraZeneca buys Hamilton-based smart cancer drug maker Fusion Pharmaceuticals for $2-billion
Brian Bloom, Chairman and Chief Executive Officer of Bloom Burton & Co. comments in the following Globe and Mail coverage on the acquisition of Fusion Pharmaceuticals (NASDAQ: FUSN) by AstraZeneca (LSE, NASDAQ: AZN).
